Navigation Links
Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
Date:10/20/2010

RICHMOND, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2010 financial results on Wednesday, October 27, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 18839232.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 27, 2010 to midnight ET on November 3, 2010. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 18839232.  

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
4. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
7. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
8. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
11. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Minn. , Dec. 7, 2016  Vyriad Inc. ... to the company,s Board of Directors. ... as we build our business and develop our oncolytic ... cancer therapy," said Stephen Russell , MD, PhD, ... Agnes , share our vision and passion for making ...
(Date:12/7/2016)... 7, 2016  Genprex, Inc. a biopharmaceutical company ... treatments, today announced that it has retained ICR ... strategic communications and advisory firm, to develop and ... will combine investor relations, public relations and digital ... profile of Genprex and its lead candidate Oncoprex, ...
(Date:12/7/2016)... , Dec. 7, 2016  Muse bio, a ... technologies, today announced that Dr. Kevin Ness ... the Board of Directors. Kevin succeeds ... becomes the company,s Chief Science Officer as well as ... Director of the BioDesign Center at the RAS Energy ...
(Date:12/7/2016)... NEW YORK and ANN ARBOR, ... a privately held biopharmaceutical company developing breakthrough immune modulatory ... clinical trial of the Company,s lead therapeutic candidate, LYC-30937- ... Psoriasis is often a debilitating skin disease that is ... the United States , with approximately ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):